• Accueil >
  • Publications >
  • AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

1 janv. 2024Nanoscale

DOI : 10.1039/d3nr04777f

Auteurs

Léna Carmès, Guillaume Bort, François Lux, Léa Seban, Paul Rocchi, Zeinaf Muradova, Agnès Hagège, Laurence Heinrich-Balard, Frédéric Delolme, Virginie Gueguen-Chaignon, Charles Truillet, Stephanie Crowley, Elisa Bello, Tristan Doussineau, Michael Dougan, Olivier Tillement, Jonathan D. Schoenfeld, Needa Brown, Ross Berbeco

Résumé

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints.

Membres

GUILLAUME BORT

Chargé de recherche CNRS

GUILLAUME BORT

Chargé de recherche CNRS